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are being managed with decompression and fusion in the US, with perioperative opioid use. 4, 8, 17, 21, 23, 28 Several studies have evaluated the relationship between spine surgery and long-term opioid use. 8, 28, 30 Approximately 0.1% of patients with underlying mental health disorders have been shown to continue prolonged opioid use following surgery. 4, 8, 21, 28 Opioid dependency in these patients causes significant financial burden on the health care system and also affects quality of life. 6, 12, 14, 31 The total economic burden of opioid overdose, abuse, and dependency has been estimated to be $78.5 billion in the US. 12, 24 The mean adjusted peruser total cost of prescription medications for spine problems increased from $166 to $397 (139%) over the past decade. Increasing use of preoperative opioids has been shown to be associated with prolonged hospital length of stay (LOS; each 100-mg morphine equivalent extends the hospital LOS by 1.1 days), delay in return to work, adverse functional outcome, and postoperative opioid dependency. 1, [3] [4] [5] 8, 22 Recently, there has been widespread use of national databases to answer clinical questions on a larger scale. 2, 8, 9, 21, 29 To that end, we aimed to identify health care utilization and overall costs based on opioid dependence in patients undergoing surgery for DS using a national database. To the best of our knowledge, this is the first study focusing on the economic burden related to the surgical management of this patient cohort.
Methods

Data Source
We used MarketScan data from Truven Health Analytics, part of IBM Watson Health. This database is constructed using paid insurance claims from approximately 100 payers and is available to researchers for a fee. Included in MarketScan are longitudinal clinical utilization of health care resources, insurance enrollment, costs associated with the treatment, and provider information 13 across different services over the time of patient enrollment for covered individuals and their dependents. The data contain a unique encrypted identification number for each patient that is used to extract data across different files.
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It has been used in medical and outcomes research since 1990. 13 We used a custom file consisting of neurology/neurosurgery inpatient, outpatient, and prescription medication data files from commercial claims and encounters, and Medicare supplemental and Medicaid databases. For this study, we extracted data related to health care utilization and costs associated with opioid dependence in patients undergoing surgery for DS.
Patient Selection, Exploratory Variables, and Follow-Up
We used the inpatient admission tables to extract patients with a primary diagnosis of acquired lumbar spondylolisthesis (ICD-9-CM code 738.4) with a concurrent procedure of either a laminectomy or fusion using ICD-9 and CPT-4 codes (laminectomy: ICD-9 codes 03.0 or 03.09, or CPT-4 codes 63005, 63012, 63017, 63030, 63042, 63047, 63056, and 63102; fusion: ICD-9 codes 81.06, 81.07, and 81.08, or CPT-4 codes 22558, 22630, and 22612). Cases with concurrent refusion (ICD-9 codes 81.36, 81.37, and 81.38; CPT-4 codes 22830, 22849, 22850, 22852, 22855) or under 18 years of age were excluded. For each patient, the first occurring case satisfying the above conditions was flagged as the index hospitalization.
Patient characteristics at the index hospitalization including age, sex, year of index hospitalization, insurance type (commercial, Medicaid, Medicare), comorbidities, and instrumentation and number of levels were used as the variables. We used the Elixhauser comorbidity score, 10 which was calculated based on modified ICD-9-CM codes (Quan et al. 27 ). Cases were classified as instrumented if the CPT-4 procedure codes 22840-22847 were present in the claims. Similarly, cases were classified as multiple-level surgery if ICD-9 procedure codes 81.62, 81.63, 81.64, or CPT-4 procedure codes 22585, 22632, 22614, 63035, 63044, 63048, 63057, 63103, or 22842-22847 were present.
To calculate the look-back period (preoperative follow-up time) and the follow-up time, we used the dates of start and end enrollment times according to the formulas below:
Pre-follow-up time = surgery admission date − start enrollment date Post-follow-up time = end enrollment date − surgery discharge date If the start or end enrollment dates fell outside our data, they were censored, respectively, with the beginning of our data (January 1, 2000) or the last date of our data (December 31, 2012).
Opioid Dependence and Analysis Groups
Presurgery (within 12 months prior to the procedure) and postsurgery opioid dependency (3-15 months following discharge) was determined using either ICD 8, 20 such as buprenorphine, butorphanol, codeine phosphate, dihydrocodeine, fentanyl citrate, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine sulfate, nalbuphine, opium alkaloids, oxycodone, oxymorphone, pentazocine, propoxyphene, tapentadol, tramadol, buprenorphine, or naltrexone; 19 or a prescription for medications (buprenorphine or naltrexone)/psychotherapy (CPT-4 code 4306F) 7 related to the management of opioid addiction disorder during the study period.
We defined the comparative groups based on opioid dependence before and after surgery as follows: group NDND (prior nondependent who remains nondependent), group NDD (prior nondependent who becomes dependent), group DND (prior dependent who becomes nondependent), and group DD (prior dependent who remains dependent).
Postoperative Outcomes
The outcomes of interest in this study were: LOS during index hospitalization following surgery; discharge disposition; complications (renal, cardiac, general neurosurgi-cal, general neurological, deep vein thrombosis [DVT] or pulmonary embolism [PE] , pulmonary, infection, wound infection, hydrocephalus, mechanical ventilation, laceration, or CSF rhinorrhea); health care resource use (hospital days, 30-day hospital readmission, and emergency department [ED] ) and health care resource costs; outpatient services; and medication refills, with their associated payments among the 4 groups (NDND, NDD, DND, DD).
Complications
The ICD-9 codes used to search for complications are listed in Table 1 . The incidence of complications was evaluated during the index hospitalization and 30 days after surgery. The presence of a complication was noted as the occurrence of any of the complication types described above. Index hospitalization complications were complications that occurred during the index procedure hospitalization. Thirty-day complications were evaluated by examining all hospitalizations and/or outpatient visits within 30 days after surgery discharge.
Health Care Resources Use
We investigated the index hospitalization and the postdischarge health care resources use. For the index hospitalization, we investigated the LOS and discharge disposition. For postdischarge health resource use outcomes, we focused on 30-day hospital readmission and outpatient emergency room (ER) use, 3-month and 3-15-month hospital admissions, outpatient services, and medication refills.
Health Care Resources Payment
We evaluated all the payments associated with the uses described in the paragraph above: index hospitalization payment, and postdischarge inpatient, outpatient, and medication payments. Payments were cumulated over all hospitalizations (inpatient payment), all outpatient services (outpatient payments), all prescription medication refills (medications payments), and a combination of all three. Outpatient ER services were a subset of the outpatient services with an indicator that they occurred in the ED. All payments were inflated to 2012 US dollars using the medical component of the consumer price index, which can be accessed through the website of the US Bureau of Labor Statistics. 25 
Statistical Analysis
We summarized continuous variables using means and standard deviations, medians and interquartile ranges (IQRs), as well as the full range (minimum to maximum). Categorical variables were summarized using counts and percentages. To compare the patient characteristics and outcomes among different opioid use groups, we used the Kruskal-Wallis test for continuous variables and the chisquare test for categorical variables. 18 We also performed a multivariable analysis for each outcome using the linear regression on log-transformed values for continuous outcomes and the logistic regression for categorical outcomes. The covariate procedure types, sex, age, Elixhauser index, insurance type, and number of levels were added to the model in addition to the opioid dependence group. From these models, we build linear contrasts to compare different groups to the reference group (NDND). Adjusted comparisons were presented in terms of relative risk (RR) for continuous variables and odds ratio (OR) for categorical variables. We used SAS software (version 9.4, SAS Institute, Inc.) for data preprocessing and data analysis.
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Results
Patient Demographics
A cohort of 10,708 patients who underwent surgery for DS was identified using the MarketScan database: 81.57%, 3.58%, 8.54%, and 6.32% of patients were in groups NDND, NDD, DND, and DD, respectively. The overall median age was 61 years and 65.1% of patients were females. Group DD had significantly more younger females compared to the NDND group (median age 57 vs 61 years, female sex 69.7% vs 64.2%). Similarly, significantly more patients in group DD had primarily commercial insurance (69.4%) compared with those in groups NDND (60.7%), NDD (64.5%), and DND (60.5%; p < 0.001). There was no significant difference in the Elixhauser comorbidity index among the different groups (p = 0.3493). Overall, the majority of patients (94%) underwent decompression with fusion for DS: 96.3% of patients in group DD had decompression with fusion compared with 93.6% in group NDND, however, the majority of patients who underwent decompression alone were in group NDND compared to those in group DD (6.41% vs 3.69%). The demographics and other patient and treatment characteristics are noted in Table 2 .
Index Hospitalization Outcomes
Overall, the median hospital LOS was 3 days, with the longest in the NDD group (4 days; Table 3 ). Compared to the NDND group, the hospital LOS was significantly longer (p < 0.001) in groups NDD (RR 1.058, 95% CI 1.005-1.114), DND (RR 1.087, 95% CI 1.05-1.124), and DD (RR 1.088, 95% CI 1.046-1.132; Table 4 ).
In all, 83.55% of patients (n = 8947) were discharged home and 9.5% (n = 1018) had in-hospital complications. Patients in groups DD and DND were less likely to be discharged home compared with those in group NDND (OR 0.639, 95% CI 0.52-0.785, and OR 0.828, 95% CI 0.691-0.992). No significant difference in terms of in-hospital complications was noted among the groups (p = 0.9062).
The median cost of index hospitalization for the combined cohort was $40,095. Patients in the DD group had a median cost of $43,524, compared with $39,654 for patients in group NDND, $41,052 in group NDD, and $41,027 in group DND (p = 0.0351). However, on adjusted analysis, these differences were not significant (p = 0.7814; Tables 3 and 4 , Fig. 1 ).
Thirty-Day Postdischarge Outcomes
At 30 days after discharge, 6.79% (n = 727), 3.46% (n = 371), and 6.47% (n = 693) of all patients were noted to have complications, hospital readmissions, and ER readmissions, respectively. However, there was no significant difference among the groups in terms of complications (p > 0.05).
Patients in the NDD group had the highest number of patients with hospital (7.05%) and ER (9.4%) readmissions at 30 days follow-up compared with those in other groups. On adjusted analysis, patients in the NDD group were 2.1 times and 61% more likely to have hospital and ER readmissions compared with those in the NDND group (p = 0.023 and 0.008, respectively; Tables 3 and 4) .
Postdischarge Outcomes at 3 Months and 3-15 Months
At 3 months following discharge, 6.12% (n = 655) of all patients were readmitted. Compared to patients in the NDND group, patients in the NDD, DND, and DD groups were 2.2 times, 42%, and 88% more likely to have hospital readmissions (p < 0.001). Patients in the DD group incurred 42% higher outpatient costs, 2.6 times higher medication refill costs, and 2.1 times higher overall costs compared with those in the NDND group (p < 0.001, Fig. 2) .
At 3-15 months after discharge, overall 19% of patients were readmitted, and median outpatient cost, medication cost, and overall costs were $4831, $1959, and $8987, respectively. Patients who were opioid dependent after surgery (groups NDD and DD) were 3.6 and 2.9 times more likely to have hospital readmissions compared to those in the NDND group. Also, patients in group DD incurred 21% higher hospital readmission costs compared to those in the NDND group. Patients in groups NDD and DD were likely to incur 2.8 times the overall costs compared to patients in group NDND (p < 0.001) at 3-15 months 
Discussion
In our cohort of 10,708 patients, we found that patients who remain opioid dependent (DD and NDD) after surgery for DS had longer hospital LOSs and were less likely to be discharged home compared with those who were opioid nondependent prior to surgery and remained nondependent (NDND) after surgery. Also, at 3-15 months, patients in the DD group incurred 21% higher hospital readmission costs compared with those in the NDND group. Patients in groups NDD and DD were likely to incur 2.8 times the overall costs compared with patients in group NDND, causing a significant health care burden.
The incidence of opioid dependence following major surgery in opioid-naïve patients varies from 0.1% to 0.4%. 4, 8, 21, 28, 31 Open procedures, preprocedure opioid dependence, and mental illness are identified as risk factors for developing long-term opioid dependence. 4, 8, 28, 31 In our study, we found that 3.58% of opioid-naïve patients developed new-onset opioid dependence following surgery for DS.
Using the Nationwide Inpatient Sample (NIS), a recent study reported that 48,911 patients underwent surgery for DS in the US from 2001 to 2010 23 with a substantial increase in the use of interbody fusion techniques in the last decade. 17, 23 In this study, 64% of patients were female and the average age was 59.7 years, 23 which are demographics comparable to our study (65% female and mean age 61 years). The majority of patients in this study underwent posterior/transforaminal lumbar interbody fusion-only procedures (83.9%, n = 41,051) followed by posterolateral fusion-only procedures (10.2%, n = 4989) for DS in this study. 23 In our study, the median LOS for the combined cohort was 3 days (range 2-4 days). Our results are comparable to another NIS-based study, 23 which reported an average LOS of 4.4 days. We found that, compared to the NDND group, the median LOS was significantly longer in the NDD, DND, and DD groups (p < 0.001). In contrast, Walid et al. 33 reported that there was no correlation (p > 0.1) between preoperative opioid dependence and LOS in a cohort of 150 patients who underwent surgery for a variety of cervical and lumbar pathologies. However, this study did not examine postoperative opioid dependence and also analyzed heterogeneous spine pathologies. Based on our results, patients who were opioid dependent either prior to or after surgery for DS tend to have longer LOS following surgery for DS, compared with those who were opioid nondependent prior to and after surgery (NDND group). The overall incidence of in-hospital complications in our study was 9.5% compared to 22.5% in the study using the NIS database (n = 48,911). 23 This difference may be attributed to the selection bias in our study (patients with at least 12 months of follow-up prior to and after surgery were included). There was no difference in both in-hospital and 30-day complication rates among different groups in our study, which implies that opioid dependence has no correlation with complications following surgery for DS.
In our study, the overall median cost of index hospitalization was $40,095. Patients in the DD group had a median cost of $43,524, compared with $39,654 for patients in group NDND, $41,052 in group NDD, and $41,027 in group DND (p = 0.0351). However, there was no significant difference among the groups on adjusted analysis (p > 0.05). Another NIS-based study reported a weighted index hospitalization cost of $61,766 in patients undergoing surgery for DS. 23 Another study reported that combined medical and pharmaceutical expenditure during the 2-year period following lumbar fusion surgeries for degenerative conditions was $12,283/individual. 21 Similarly, we found that additional combined median inpatient, outpatient, and medication costs during the 15-month period after the index hospitalization cost of the surgery for DS was $11,255 per patient. Also in our study, patients in the DD group had 2.1 and 2.8 times higher overall costs at 3 months and 3-15 months, respectively, compared to patients in the NDND group (p < 0.001). This finding has important implications for routine clinical practice; various measures to reduce opioid dependence (psychiatric consultation, behavior therapy, etc.) should be considered prior to elective spine surgery. These measures can help reduce overall health care costs in this patient population.
Limitations of the Study
A major advantage of using the MarketScan database is that it provides longitudinal information related to inpatient and outpatient services that are inclusive of medication refills and health care utilization costs, in a large sample size across the US, thereby providing an opportunity to answer a clinically relevant question on a wider scale.
The limitations of using such a database include the retrospective nature of the study and inherent limitations associated with such methodology. Moreover, this database is based on insurance claims, which were used to charge in-hospital/outpatient services and medication costs during the treatment. Therefore, this study did not take into account the clinical scenario and thought process in the management as well the clinical follow-up of an individual patient. Other potential limitations include coding errors, inability to track the "actual consumption" of the opioid by the patient, and inability to capture the patients who were obtaining illegal opioids, which may over-or underestimate the actual clinical scenario. Despite these limitations, our study provides an in-depth analysis of the impact of opioid dependency on health care utilization at different time points in patients undergoing surgery for DS.
Conclusions
Patients who continued to be opioid dependent or become opioid dependent following surgery for DS incur significant health care utilization and costs at 3 months and 3-15 months. These findings can be used to formulate strategies to reduce the health care costs in this patient population, given the current scenario of the opioid crisis.
